Fam-trastuzumab deruxtecan-nxki ds8201

Fam-trastuzumab deruxtecan-nxki (Fam-trastuzumab deruxtecan-nxki) is a new type of injectable anti-cancer drug. In the clinical research stage, its name may be ds8201, or it may also be called T-Dxd. Trastuzumab is approved to be marketed overseas under the trade name Enhertu, and in China under the trade name Enhertu, both are the same drug.

Trastuzumab is indicated in adults with HER2-positive breast cancer that has spread to other parts of the body (metastatic) or cannot be removed with surgery, in adults who have previously received anti-HER2 breast cancer treatment for metastatic disease, or in patients whose breast cancer has come back within 6 months of completing treatment for early-stage breast cancer. Trastuzumab can also be used in adults to treat certain types of HER2-positive gastric or esophageal cancer, and can also be used in adults non-small cell lung cancer with HER2 (ERBB2) mutations. Trastuzumab is usually used after other cancer treatments have not worked or stopped working, and may also be used for purposes not listed in this Medication Guide.

The trastuzumab generic drug currently on the market in China has not yet entered the scope of medical insurance. It is a strictly controlled drug and its purchase is restricted. The Hong Kong version of trastuzumab specifications currently sold in Hong Kong may cost more than 10,000 yuan per box of 100 mg. The Hong Kong original version of trastuzumab original drug specificationsThe price of each box of 100mg may be around RMB 15,000 (the price may fluctuate due to the exchange rate). The drug ingredients of the two are basically the same. There is currently no generic version of Trastuzumab on the market. For more specific prices and drug information, please consult Yade’s medical consultant.